The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Compulsive drug use linked to sensitized ventral striatal dopamine transmission.
Abstract
OBJECTIVE: A small group of Parkinson's disease (PD) patients compulsively use dopaminergic drugs despite causing harmful social, psychological, and physical effects and fulfil core Diagnostic and Statistical Manual (of Mental Disorders) Fourth Edition criteria for substance dependence (dopamine dysregulation syndrome [DDS]). We aimed to evaluate levodopa-induced dopamine neurotransmission in the striatum of patients with DDS compared with PD control patients. METHODS: We used a two-scan positron emission tomography protocol to calculate the percentage change in (11)C-raclopride binding potential from a baseline withdrawal (off drug) state to the binding potential after an oral dose of levodopa. We related the subjective effects of levodopa to the effects on endogenous dopamine release of a pharmacological challenge with levodopa in eight control PD patients and eight patients with DDS. RESULTS: PD patients with DDS exhibited enhanced levodopa-induced ventral striatal dopamine release compared with levodopa-treated patients with PD not compulsively taking dopaminergic drugs. The sensitized ventral striatal dopamine neurotransmission produced by levodopa in these individuals correlated with self-reported compulsive drug "wanting" but not "liking" and was related to heightened psychomotor activation (punding). INTERPRETATION: This provides evidence that links sensitization of ventral striatal circuitry in humans to compulsive drug use.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similarly, it is now increasingly clear that increases of human dopamine do not reliably cause enhancement of subjective ratings of pleasure (although many rewards do induce dopamine release as a consequence and correlate, but not the cause, of pleasure) (Leyton et al., 2002; Evans et al., 2006; Liggins et al., 2012).”
From Evolving Concepts of Emotion and Motivation (2018) · cites this paper as Evans et al., 2006
In the citing paper
“Dopamine surges in nucleus accumbens evoked by addictive amphetamine or by L-DOPA correlate poorly with human subjective liking ratings of the drug - but do control their subjective wanting ratings to take more of that drug (Leyton et al., 2002; Evans et al., 2006).”
From Evolving Concepts of Emotion and Motivation (2018) · cites this paper as Evans et al., 2006
In the citing paper
“Similarly, it is now increasingly clear that increases of human dopamine do not reliably cause enhancement of subjective ratings of pleasure (although many rewards do induce dopamine release as a consequence and correlate, but not the cause, of pleasure) (Leyton et al., 2002; Evans et al., 2006; Liggins et al., 2012).”
From Evolving Concepts of Emotion and Motivation (2018) · cites this paper as Evans et al., 2006
Citations
Cites
Development and validation of brief measures of positive and negative affect: The PANAS scales.
Watson, D., Clark, L. A., & Tellegen, A. (1988) · Journal of Personality and Social Psychology · doi:10.1037/0022-3514.54.6.1063 · Cited by 32,433
The neural basis of drug craving: An incentive-sensitization theory of addiction
Robinson, T. (1993) · Brain Research Reviews · doi:10.1016/0165-0173(93)90013-p · Cited by 7,346
Carver, C. S., & White, T. L. (1994) · Journal of Personality and Social Psychology · doi:10.1037/0022-3514.67.2.319 · Cited by 7,306
A psychobiological model of temperament and character
Cloninger, C. R. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820240059008 · Cited by 5,458
Di Chiara, G., & Imperato, A. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.14.5274 · Cited by 4,733
A psychomotor stimulant theory of addiction.
Wise, R. A., & Bozarth, M. A. (1987) · Psychological Review · doi:10.1037/0033-295x.94.4.469 · Cited by 2,747
(1994) · Cited by 2,675
Recent Developments in Parkinson's Disease
Hurtig, H. I. (1987) · Neurology · doi:10.1212/wnl.37.5.893 · Cited by 1,925
Behavioral expressions and biosocial bases of sensation seeking
Corr, P. J. (1995) · Personality and Individual Differences · doi:10.1016/0191-8869(95)90059-4 · Cited by 1,525
The psychology and neurobiology of addiction: an incentive–sensitization view
Robinson, T. E., & Berridge, K. C. (2000) · Addiction · doi:10.1046/j.1360-0443.95.8s2.19.x · Cited by 1,507
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 473
Gender differences in the motivational processing of facial beauty
Levy, B., Dan Ariely, C., Mažar, N., Chi, W., Lukas, S. E., & Elman, I. (2007) · Learning and Motivation · doi:10.1016/j.lmot.2007.09.002 · Cited by 76
“Wanting,” “liking,” and their relation to consciousness.
Anselme, P., & Robinson, M. J. F. (2015) · Journal of Experimental Psychology Animal Learning and Cognition · doi:10.1037/xan0000090 · Cited by 82
Psychostimulant effect of dopaminergic treatment and addictions in Parkinson's disease
Delpont, B., Lhommée, E., Klinger, H., Schmitt, E., Bichon, A., Fraix, V., Castrioto, A., Quésada, J.-L., Pélissier, P., Kistner, A., et al. (2017) · Movement Disorders · doi:10.1002/mds.27101 · Cited by 72
Infusion Therapies and Development of Impulse Control Disorders in Advanced Parkinson Disease
Todorova, A., Samuel, M., Brown, R. G., & Chaudhuri, К. R. (2015) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000091 · Cited by 72
Understanding the Placebo Effect: Contributions from Neuroimaging
Lidstone, S. C., & Stoessl, A. J. (2007) · Molecular Imaging and Biology · doi:10.1007/s11307-007-0086-3 · Cited by 75
Neuroimaging in Parkinson's Disease
Stoessl, A. J. (2011) · Neurotherapeutics · doi:10.1007/s13311-010-0007-z · Cited by 69
Management of Impulse Control and Related Disorders in Parkinson's Disease: An Expert Consensus
Debove, I., Paschen, S., Amstutz, D., Cardoso, F., Corvol, J., Fung, V. S. C., Lang, A. E., Martínez‐Martín, P., Rodríguez-Oroz, M. C., Weintraub, D. A., et al. (2024) · Movement Disorders · doi:10.1002/mds.29700 · Cited by 73
Neuropsychiatric Behaviors in the MPTP Marmoset Model of Parkinson’s Disease
Fox, S. H., Visanji, N. P., Reyes, G., Huot, P., Gómez-Ramírez, J., Johnston, T. H., & Brotchie, J. M. (2010) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100009707 · Cited by 69
Role of netrin-1 in the organization and function of the mesocorticolimbic dopamine system
Flores, C. (2011) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.100171 · Cited by 72
Impulsive and Compulsive Behaviors in Parkinson's Disease
Averbeck, B. B., O’Sullivan, S. S., & Djamshidian, A. (2013) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-032813-153705 · Cited by 73
Hellberg, S. N., Russell, T. I., & Robinson, M. J. F. (2019) · Cognitive, Affective, & Behavioral Neuroscience · doi:10.3758/s13415-018-00662-3 · Cited by 65
“DDS occurs in a small proportion of Parkinson’s patients being treated with dopamine agonist medication (Dodd et al., 2005; Evans, Lawrence, Cresswell, Katzenschlager, & Lees, 2010; Evans et al., 2006).”
Unraveling the Temporal Dynamics of Reward Signals in Music-Induced Pleasure with TMS
Herrero, E. M., Dagher, A., Franch, M. F., & Zatorre, R. J. (2021) · Journal of Neuroscience · doi:10.1523/jneurosci.0727-20.2020 · Cited by 69
Hyperdopaminergic behavioral spectrum in Parkinson's disease: A review
Béreau, M., Fleury, V., Bouthour, W., Castrioto, A., Lhommée, E., & Krack, P. (2018) · Revue Neurologique · doi:10.1016/j.neurol.2018.07.005 · Cited by 63
The Cambridge Handbook of Substance and Behavioral Addictions
Sussman, S. Y. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108632591 · Cited by 64
Apathy in Parkinson’s Disease: Clinical Patterns and Neurobiological Basis
Béreau, M., Waes, V. V., Servant, M., Magnin, É., Tatu, L., & Anheim, M. (2023) · Cells · doi:10.3390/cells12121599 · Cited by 66
Castrioto, A., Funkiewiez, A., Debu, B. H. G., Cools, R., Lhommée, E., Ardouin, C., Fraix, V., Chabardès, S., Robbins, T. W., Pollak, P., et al. (2014) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2013-307146 · Cited by 62
Understanding the Placebo Effect: Contributions from Neuroimaging
Lidstone, S. C., & Stoessl, A. J. (2007) · Molecular Imaging and Biology · doi:10.1007/s11307-007-0098-z · Cited by 61
The role of dopamine pharmacotherapy and addiction-like behaviors in Parkinson’s disease
Napier, T. C., Kirby, A. E., & Persons, A. L. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.109942 · Cited by 60
Aberrant reward processing in Parkinson's disease is associated with dopamine cell loss
Aarts, E., Helmich, R. C. G., Janssen, M. J. R., Oyen, W. J. G., Bloem, B. R., & Cools, R. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2011.11.073 · Cited by 67
Predictors of punding in Parkinson's disease: Results from a questionnaire survey
Lawrence, A. J., Blackwell, A. D., Barker, R. A., Spagnolo, F., Clark, L., Aitken, M. R. F., & Sahakian, B. J. (2007) · Movement Disorders · doi:10.1002/mds.21702 · Cited by 59
Self-citationLateral thinking about leptin: A review of leptin action via the lateral hypothalamus
Leinninger, G. M. (2011) · Physiology & Behavior · doi:10.1016/j.physbeh.2011.04.060 · Cited by 62
The dopamine augmenter L-DOPA does not affect positive mood in healthy human volunteers.
Liggins, J., Pihl, R. O., Benkelfat, C., & Leyton, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0028370 · Cited by 58
Excessive hoarding in Parkinson's disease
O’Sullivan, S. S., Djamshidian, A., Evans, A. H., Loane, C., Lees, A. J., & Lawrence, A. D. (2010) · Movement Disorders · doi:10.1002/mds.23016 · Cited by 58
Self-citationKnobel, D., Aybek, S., Pollo, C., Vingerhoets, F. J. G., & Berney, A. (2008) · Cognitive and Behavioral Neurology · doi:10.1097/wnn.0b013e318185e6e2 · Cited by 57
The role of dopamine in risk taking: a specific look at Parkinson’s disease and gambling
Clark, C. A., & Dagher, A. (2014) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2014.00196 · Cited by 69
Impulse-Control Disorders in Parkinson's Disease
Ferrara, J. M., & Stacy, M. A. (2008) · CNS Spectrums · doi:10.1017/s1092852900013778 · Cited by 57
Dopamine receptor mapping with PET imaging in Parkinson’s disease
Niccolini, F., Su, P., & Politis, M. (2014) · Journal of Neurology · doi:10.1007/s00415-014-7302-2 · Cited by 54
Extrastriatal dopaminergic changes in Parkinson's disease patients with impulse control disorders
Lee, J., Seo, S. H., Kim, Y. K., Yoo, H. B., Kim, Y. E., Song, I. C., Lee, J., & Jeon, B. S. (2013) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2013-305549 · Cited by 55
Salivary cortisol levels in Parkinson's disease and its correlation to risk behaviour
Djamshidian, A., O’Sullivan, S. S., Papadopoulos, A. S., Bassett, P., Shaw, K., Averbeck, B. B., & Lees, A. J. (2011) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2011.245746 · Cited by 59
Self-citationKorb, S., Götzendorfer, S. J., Massaccesi, C., Sezen, P., Graf, I., Willeit, M., Eisenegger, C., & Silani, G. (2020) · eLife · doi:10.7554/elife.55797 · Cited by 53
Changing Gears – DBS For Dopaminergic Desensitization in Parkinson's Disease?
Weiß, D., Volkmann, J., Fasano, A. A., Kühn, A. A., Krack, P., & Deuschl, G. (2021) · Annals of Neurology · doi:10.1002/ana.26164 · Cited by 53
On Cue: Striatal Ups and Downs in Addictions
Leyton, M., & Vezina, P. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.04.036 · Cited by 53
Levodopa gains psychostimulant‐like properties after nigral dopaminergic loss
Engeln, M., Fasano, S., Ahmed, S. H., Cador, M., Baekelandt, V., Bézard, E., & Fernagut, P. (2013) · Annals of Neurology · doi:10.1002/ana.23881 · Cited by 53
Pathological gambling in Parkinson's disease—a review of the literature
Djamshidian, A., Cardoso, F., Grosset, D. G., Bowden‐Jones, H., & Lees, A. J. (2011) · Movement Disorders · doi:10.1002/mds.23821 · Cited by 56
Self-citationLevodopa treatment and dendritic spine pathology
Nishijima, H., Ueno, T., Funamizu, Y., Ueno, S., & Tomiyama, M. (2017) · Movement Disorders · doi:10.1002/mds.27172 · Cited by 52
Dopamine agonist‐induced pathological gambling in restless legs syndrome due to multiple sclerosis
Evans, A. H., & Butzkueven, H. (2007) · Movement Disorders · doi:10.1002/mds.21303 · Cited by 52
Self-citationCompulsive use of dopaminergic drug therapy in Parkinson's disease: Reward and anti‐reward
Evans, A. H., Lawrence, A. D., Cresswell, S. A., Katzenschlager, R., & Lees, A. J. (2010) · Movement Disorders · doi:10.1002/mds.22898 · Cited by 51
Self-citationImpulse control disorders in Parkinson’ disease: the role of personality and cognitive status
Poletti, M., & Bonuccelli, U. (2012) · Journal of Neurology · doi:10.1007/s00415-012-6506-6 · Cited by 51
Frontostriatal Cognitive Staging in Parkinson's Disease
de la Fuente‐Fernández, R. (2011) · Parkinson s Disease · doi:10.1155/2012/561046 · Cited by 50
Wu, K., Politis, M., O'Sullivan, S., Lawrence, A., Warsi, S., Bose, S., Lees, A., & Piccini, P. (2015) · Journal of Neurology · doi:10.1007/s00415-015-7722-7 · Cited by 50
Self-citationFenu, S., Wardas, J., & Morelli, M. (2009) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e32833109a0 · Cited by 49
Functional brain imaging of cognitive dysfunction in Parkinson's disease
Hirano, S., Shinotoh, H., & Eidelberg, D. (2012) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2011-301818 · Cited by 50
Neuropsychiatry of Parkinson's disease
Kümmer, A., & Teixeira, A. L. (2009) · Arquivos de Neuro-Psiquiatria · doi:10.1590/s0004-282x2009000500033 · Cited by 49
Reed, D. D., Naudé, G. P., Gelino, B. W., & Amlung, M. T. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108632591.011 · Cited by 48
Averbeck, B. B., Djamshidian, A., O’Sullivan, S. S., Housden, C. R., Roiser, J. P., & Lees, A. J. (2013) · Behavioral Neuroscience · doi:10.1037/a0032079 · Cited by 48
Self-citationZonisamide for the Treatment of Parkinson Disease: A Current Update
Li, C., Li, X., Liu, Y., Yang, Z., Chi, S., & Xie, A. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.574652 · Cited by 48
Okai, D., Samuel, M., Askey‐Jones, S., David, A. S., & Brown, R. G. (2011) · European Journal of Neurology · doi:10.1111/j.1468-1331.2011.03432.x · Cited by 47
Structural and Functional Brain Patterns of Non-Motor Syndromes in Parkinson’s Disease
Prell, T. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00138 · Cited by 48
Dopamine-Induced Nonmotor Symptoms of Parkinson's Disease
Park, A., & Stacy, M. A. (2011) · Parkinson s Disease · doi:10.4061/2011/485063 · Cited by 47
Paraphilias and paraphilic disorders in Parkinson's disease: a systematic review of the literature
Solla, P., Bortolato, M., Cannas, A., Mulas, C. S., & Marrosu, F. (2015) · Movement Disorders · doi:10.1002/mds.26157 · Cited by 46
Clinical aspects of impulsive compulsive behaviours in Parkinson's disease
Djamshidian, A., Averbeck, B. B., Lees, A. J., & O’Sullivan, S. S. (2011) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2011.07.031 · Cited by 46
Self-citationPsychostimulant effect of levodopa: reversing sensitisation is possible
Castrioto, A., Kistner, A., Klinger, H., Lhommée, E., Schmitt, E., Fraix, V., Chabardès, S., Mertens, P., Quesada, J., Broussolle, E., et al. (2012) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-302444 · Cited by 42
The Prevention and Treatment of Gambling Disorders: Some Art, Some Science
Derevensky, J. L. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108632591.024 · Cited by 45
Jiménez‐Urbieta, H., Gago, B., de la Riva, P., Delgado‐Alvarado, M., Marı́n, C., & Rodríguez-Oroz, M. C. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.07.010 · Cited by 50
New developments in depression, anxiety, compulsiveness, and hallucinations in Parkinson's disease
Goetz, C. G. (2010) · Movement Disorders · doi:10.1002/mds.22636 · Cited by 45
Houéto, J., Magnard, R., Dalley, J. W., Belin, D., & Carnicella, S. (2016) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2016.00091 · Cited by 48
Considering the Overlap and Nonoverlap of Compulsivity, Impulsivity, and Addiction
Blum, A. W., & Grant, J. E. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108632591.038 · Cited by 44
Neurobiological Foundations of Behavioral Addictions
Vaccaro, A. G., & Potenza, M. N. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108632591.016 · Cited by 45
Neurobiology of Substance Addictions
Christie, N. C., & Bechara, A. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108632591.015 · Cited by 44
Sensitization of Incentive Salience and the Transition to Addiction
Warlow, S. M., Baumgartner, H. M., Freeland, C. M., Naffziger, E. E., Olney, J. J., Berridge, K. C., & Robinson, M. J. F. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108632591.006 · Cited by 46
Dopaminergic dysregulation syndrome in Parkinson's disease
Katzenschlager, R. (2011) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2011.07.012 · Cited by 44
Mindfulness-Based Interventions Applied to Addiction Treatments
Kechter, A., & Black, D. S. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108632591.040 · Cited by 43
Multiple Memory Systems, Addiction, and Health Habits: New Routes for Translational Science
Stacy, A. W., Pike, J. R., & Lee, A. Y. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108632591.017 · Cited by 43
Tanning as an Addiction: The State of the Research and Implications for Intervention
Miller, K. A., & Mays, D. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108632591.037 · Cited by 43
Schulte, E. M., Schiestl, E. T., & Gearhardt, A. N. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108632591.035 · Cited by 43
Treatment of advanced Parkinson’s disease
Diamond, A. L., & Jankovic, J. J. (2006) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.6.8.1181 · Cited by 43
Behavioral Economics and Addictive Disorders
Jarmolowicz, D. P., & Schneider, T. D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108632591.005 · Cited by 42
Prevention and Treatment of Compulsive Buying Disorder
Galimov, A., & Black, D. W. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108632591.027 · Cited by 42
Blum, K., Roy, A. K., Podesta, A., Modestino, E. J., Steinberg, B., Gondré-Lewis, M. C., Baron, D. A., Thanos, P. K., Lott, L., Badgaiyan, S., et al. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108632591.031 · Cited by 42
Prevention and Treatment of “Food Addiction”
Davis, C., & Mason, A. E. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108632591.023 · Cited by 42
Human Neurobiological Approaches to Hedonically Motivated Behaviors
Burger, K. S., Shearrer, G. E., & Sadler, J. R. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108632591.009 · Cited by 42
Feedback Models for Gambling Control: The Use and Efficacy of Online Responsible Gambling Tools
Griffiths, M. D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108632591.034 · Cited by 42
Ceravolo, R., Frosini, D., Rossi, C., & Bonuccelli, U. (2010) · Journal of Neurology · doi:10.1007/s00415-010-5715-0 · Cited by 41
Suggestive association between OPRM1 and impulse control disorders in Parkinson's disease
Cormier‐Dequaire, F., Bekadar, S., Anheim, M., Lebbah, S., Pélissolo, A., Krack, P., Lacomblez, L., Lhommée, E., Castrioto, A., Azulay, J., et al. (2018) · Movement Disorders · doi:10.1002/mds.27519 · Cited by 45
Neurological considerations: Autism and Parkinson's disease
Hollander, E., Wang, A. T., Braun, A. R., & Marsh, L. (2009) · Psychiatry Research · doi:10.1016/j.psychres.2008.07.014 · Cited by 44
Management of psychiatric disorders in Parkinson's disease
Weintraub, D. A. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00875-w · Cited by 42
Genetic prediction of impulse control disorders in Parkinson's disease
Weintraub, D. A., Posavi, M., Fontanillas, P., Tropea, T. F., Mamikonyan, E., Suh, E. R., Trojanowski, J. Q., Cannon, P., Deerlin, V. M. V., & Chen‐Plotkin, A. S. (2022) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51569 · Cited by 40
Johnston, T. H., Huot, P., Fox, S. H., WAKEFIELD, J. D., Sykes, K. A., Bartolini, W. P., Milne, G. T., Pearson, J. P., & Brotchie, J. M. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.169532 · Cited by 40
Amjad, F., Bhatti, D., Davis, T. L., Oguh, O., Pahwa, R., Kukreja, P., Zamudio, J., & Metman, L. V. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01014-4 · Cited by 39
The Psychiatric and Neuropsychiatric Symptoms After Subthalamic Stimulation for Parkinson’s Disease
Mosley, P. E., & Marsh, R. (2015) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.14040069 · Cited by 38
Imaging in Parkinson's Disease
Politis, M., Pagano, G., & Niccolini, F. (2017) · International review of neurobiology · doi:10.1016/bs.irn.2017.02.015 · Cited by 39
Latella, D., Maggio, M. G., Maresca, G., Saporoso, A. F., Cause, M. L., Manuli, A., Milardi, D., Bramanti, P., Luca, R. D., & Calabrò, R. S. (2019) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2019.01.034 · Cited by 38
On behalf of the EDIS Study Group, Catalán, M. J., Arjona, J. A. M., Mir, P., Cubo, E., Arbelo, J. M., & Martínez‐Martín, P. (2018) · Journal of Neurology · doi:10.1007/s00415-018-8803-1 · Cited by 39
Visanji, N. P., Fox, S. H., Johnston, T. H., Millan, M. J., & Brotchie, J. M. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.144097 · Cited by 37
Compulsive singing: another aspect of punding in Parkinson's disease
Bonvin, C., Horvath, J., Christe, B., Landis, T., & Burkhard, P. R. (2007) · Annals of Neurology · doi:10.1002/ana.21202 · Cited by 36
Impulsive and Compulsive Behaviors in Parkinson’s Disease
Zhang, G., Zhang, Z., Liu, L., Yang, J., Huang, J., Xiong, N., & Wang, T. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00318 · Cited by 40
Role of dopamine and clinical heterogeneity in cognitive dysfunction in Parkinson's disease
Cools, R., Tichelaar, J. G., Helmich, R. C. G., Bloem, B. R., Esselink, R. A. J., Smulders, K., & Timmer, M. H. M. (2022) · Progress in brain research · doi:10.1016/bs.pbr.2022.01.012 · Cited by 38
Valproate as a treatment for dopamine dysregulation syndrome (DDS) in Parkinson’s disease
Sriram, A., Ward, H. E., Hassan, A., Iyer, S. S., Foote, K. D., Rodriguez, R. L., McFarland, N. R., & Okun, M. S. (2012) · Journal of Neurology · doi:10.1007/s00415-012-6669-1 · Cited by 35
Nikolova, Y. S., & Hariri, A. R. (2012) · Biology of Mood & Anxiety Disorders · doi:10.1186/2045-5380-2-19 · Cited by 37
Janssen, L. K., Sescousse, G., Hashemi, M. M., Timmer, M. H. M., ter Huurne, N. P., Geurts, D. E. M., & Cools, R. (2015) · Psychopharmacology · doi:10.1007/s00213-015-3986-y · Cited by 35
Ramirez‐Zamora, A., Gee, L. E., Boyd, J. T., & Biller, J. (2016) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2016.1158103 · Cited by 34
Effect of Levodopa on Reward and Impulsivity in a Rat Model of Parkinson’s Disease
Carvalho, M. M., Campos, F. L., Marques, M., Soares‐Cunha, C., Kokras, N., Dalla, C., Leite‐Almeida, H., Sousa, N., & Salgado, A. J. (2017) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2017.00145 · Cited by 39
Imaging of Dopamine in PD and Implications for Motor and Neuropsychiatric Manifestations of PD
de la Fuente‐Fernández, R. (2013) · Frontiers in Neurology · doi:10.3389/fneur.2013.00090 · Cited by 32
Impulse Control Disorders and Related Complications of Parkinson's Disease Therapy
Weintraub, D., Claassen, D. O., & Lopez, A. M. (2017) · Seminars in Neurology · doi:10.1055/s-0037-1601887 · Cited by 33
Mesencephalic and extramesencephalic dopaminergic systems in Parkinson’s disease
Geibl, F. F., Henrich, M. T., & Oertel, W. H. (2019) · Journal of Neural Transmission · doi:10.1007/s00702-019-01970-9 · Cited by 34
From apathy to addiction: Insights from neurology and psychiatry
Kirschner, M., Rabinowitz, A. G., Singer, N., & Dagher, A. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.109926 · Cited by 37
Maloney, E. M., Djamshidian, A., & O’Sullivan, S. S. (2016) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2016.12.058 · Cited by 31
Barbosa, P., Hapuarachchi, B., Djamshidian, A., Strand, K. M., Lees, A. J., de Silva, R., Holton, J. L., & Warner, T. T. (2019) · Brain · doi:10.1093/brain/awz298 · Cited by 30
Self-citationImpulse control disorders in Parkinson’s disease: clinical characteristics and implications
Leeman, R. F., & Potenza, M. N. (2011) · Neuropsychiatry · doi:10.2217/npy.11.11 · Cited by 34
Carbone, F., & Djamshidian, A. (2024) · CNS Drugs · doi:10.1007/s40263-024-01087-y · Cited by 31
Metadata
- Authors
- Evans, A. H., Pavese, N., Lawrence, A. D., Tai, Y. F., Appel, S., Doder, M., Brooks, D. J., Lees, A. J., & Piccini, P.
- Affiliations
- National Hospital for Neurology and Neurosurgery (GB)
- Hammersmith Hospital (GB)
- MRC Cognition and Brain Sciences Unit (GB)
- Corresponding author
- Piccini, Paola
- ORCID
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2006-03-23
- Volume
- 59
- Issue
- 5
- Pages
- 852-858
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2115622614
- Cited by
- 473
- References
- 52
- Citations by year
- 2026: 6 · 2025: 5 · 2024: 11 · 2023: 8 · 2022: 15 · 2021: 17 · 2020: 76 · 2019: 10 · 2018: 25 · 2017: 20 · 2016: 17 · 2015: 30 · 2014: 23 · 2013: 30 · 2012: 30
- FWCI
- 15.54
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Annals of Neurology (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Keywords
- dopamine dysregulation syndrome, compulsive drug use, Parkinson's disease, ventral striatum, dopamine signaling, levodopa challenge, dopamine release, punding, drug liking, substance dependence
- MeSH terms
- Aged, Brain Mapping, Dopamine, Exploratory Behavior, Female, Humans, Levodopa, Male, Middle Aged, Synaptic Transmission, Psychological Tests, Dopamine Agents, Neostriatum, Receptors, Dopamine D2, Dopamine Antagonists, Substance-Related Disorders, Raclopride, Positron-Emission Tomography, Receptors, Dopamine D3
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
